Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares dropped 1.4% on Friday . The company traded as low as $11.54 and last traded at $12.07, with a volume of 303,586 shares trading hands. The stock had previously closed at $12.24.

AQXP has been the subject of several analyst reports. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 21st. Needham & Company LLC initiated coverage on shares of Aquinox Pharmaceuticals in a report on Thursday, May 12th. They issued a “buy” rating and a $25.00 price objective for the company. Jefferies Group raised their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $19.86.

The stock has a 50 day moving average of $8.94 and a 200-day moving average of $8.42. The stock’s market cap is $208.95 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.22. On average, equities analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.